Compare Dr. Reddys with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DIVIS LABORATORIES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DIVIS LABORATORIES DR. REDDYS LAB/
DIVIS LABORATORIES
 
P/E (TTM) x 34.9 42.5 82.1% View Chart
P/BV x 4.9 8.4 58.2% View Chart
Dividend Yield % 0.5 0.7 66.4%  

Financials

 DR. REDDYS LAB   DIVIS LABORATORIES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
DIVIS LABORATORIES
Mar-19
DR. REDDYS LAB/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,8751,639 175.4%   
Low Rs1,8881,115 169.3%   
Sales per share (Unadj.) Rs930.2186.3 499.3%  
Earnings per share (Unadj.) Rs117.451.0 230.4%  
Cash flow per share (Unadj.) Rs185.857.3 324.1%  
Dividends per share (Unadj.) Rs20.0016.00 125.0%  
Dividend yield (eoy) %0.81.2 72.3%  
Book value per share (Unadj.) Rs844.4261.8 322.6%  
Shares outstanding (eoy) m166.07265.47 62.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.67.4 34.6%   
Avg P/E ratio x20.327.0 75.0%  
P/CF ratio (eoy) x12.824.0 53.4%  
Price / Book Value ratio x2.85.3 53.6%  
Dividend payout %17.031.4 54.2%   
Avg Mkt Cap Rs m395,496365,592 108.2%   
No. of employees `00022.011.8 185.4%   
Total wages/salary Rs m33,5625,423 618.9%   
Avg. sales/employee Rs Th7,032.84,175.1 168.4%   
Avg. wages/employee Rs Th1,527.9457.7 333.8%   
Avg. net profit/employee Rs Th887.71,141.8 77.7%   
INCOME DATA
Net Sales Rs m154,48249,463 312.3%  
Other income Rs m3,3751,556 216.9%   
Total revenues Rs m157,85751,019 309.4%   
Gross profit Rs m31,78218,718 169.8%  
Depreciation Rs m11,3481,689 671.9%   
Interest Rs m88935 2,540.0%   
Profit before tax Rs m22,92018,551 123.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8585,023 76.8%   
Profit after tax Rs m19,50013,527 144.2%  
Gross profit margin %20.637.8 54.4%  
Effective tax rate %16.827.1 62.2%   
Net profit margin %12.627.3 46.2%  
BALANCE SHEET DATA
Current assets Rs m111,10146,501 238.9%   
Current liabilities Rs m58,9738,468 696.5%   
Net working cap to sales %33.776.9 43.9%  
Current ratio x1.95.5 34.3%  
Inventory Days Days79131 60.7%  
Debtors Days Days9486 109.7%  
Net fixed assets Rs m101,24525,797 392.5%   
Share capital Rs m830531 156.3%   
"Free" reserves Rs m139,40668,962 202.1%   
Net worth Rs m140,23669,493 201.8%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65680,383 279.5%  
Interest coverage x26.8531.0 5.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.6 111.7%   
Return on assets %9.116.9 53.8%  
Return on equity %13.919.5 71.4%  
Return on capital %14.926.7 55.9%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m88,67341,238 215.0%   
Fx outflow Rs m19,10412,405 154.0%   
Net fx Rs m69,56928,833 241.3%   
CASH FLOW
From Operations Rs m28,7049,543 300.8%  
From Investments Rs m-7,727-6,854 112.7%  
From Financial Activity Rs m-21,326-2,459 867.1%  
Net Cashflow Rs m-314230 -136.8%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.8 45.8%  
FIIs % 35.3 19.0 185.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.2 89.0%  
Shareholders   75,885 31,796 238.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  DR. DATSONS LABS  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 419 Points Higher; IT and Banking Stocks Witness Huge Buying(Closing)

Indian share markets continued their momentum and ended on a strong note today.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How to Find the Best Stocks for Day Trading - 2(Fast Profits Daily)

Jul 10, 2020

Use this method to identify the right stocks to trade intraday.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

From a 57% Fall to Gains of 168%. This is What a Smallcap Rebound Really Looks Like(Profit Hunter)

Jul 7, 2020

This smallcap is essential enough to continue business even amid a second wave of infections, or lockdown.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 16, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS